Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Accounts Payables (2016 - 2026)

Akebia Therapeutics has reported Accounts Payables over the past 11 years, most recently at $21.2 million for Q4 2025.

  • Quarterly Accounts Payables rose 39.56% to $21.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $21.2 million through Dec 2025, up 39.56% year-over-year, with the annual reading at $21.2 million for FY2025, 39.56% up from the prior year.
  • Accounts Payables was $21.2 million for Q4 2025 at Akebia Therapeutics, up from $10.1 million in the prior quarter.
  • Over five years, Accounts Payables peaked at $42.0 million in Q2 2021 and troughed at $9.0 million in Q3 2023.
  • The 5-year median for Accounts Payables is $14.9 million (2023), against an average of $18.6 million.
  • Year-over-year, Accounts Payables plummeted 54.14% in 2023 and then surged 49.3% in 2024.
  • A 5-year view of Accounts Payables shows it stood at $33.6 million in 2021, then plummeted by 46.35% to $18.0 million in 2022, then decreased by 18.79% to $14.6 million in 2023, then increased by 3.72% to $15.2 million in 2024, then surged by 39.56% to $21.2 million in 2025.
  • Per Business Quant, the three most recent readings for AKBA's Accounts Payables are $21.2 million (Q4 2025), $10.1 million (Q3 2025), and $11.6 million (Q2 2025).